Trevi Therapeutics Initiates Pivotal Clinical Trial of Nalbuphine® ER for the Treatment of Pruritus in Prurigo Nodularis
Pruritus Relief thru Itch-Scratch Modulation (“PRISM”) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER […]